Pasar al contenido principal

BÚSQUEDA DE NUEVAS DIANAS TERAPÉUTICAS EN ENFERMEADADES HEPÁTICAS CRÓNICAS.

RYC-2015-17755

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Investigación, Desarrollo e Innovación
Centro beneficiario ASOC INSTITUTO DE INVESTIGACION SANITARIA BIOGIPUZKOA
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis

  • Fernández Ramos, David
  • Fernández Tussy, Pablo
  • Lopitz Otsoa, Fernando
  • Gutiérrez de Juan, Virginia
  • Navasa Mayo, Nicolás
  • Barbier Torres, Lucía
  • Zubiete Franco, Imanol
  • Simón, Jorge
  • Fernández, Agustín F.
  • Arbelaiz, Ander
  • Aransay, Ana M.
  • Lavín, José Luis
  • Beraza, Naiara
  • Perugorria, Maria J.
  • Banales, Jesus M.
  • Villa, Erica
  • Fraga, Mario F.
  • Anguita, Juan
  • Ávila, Matías A.
  • Berasain, Carmen
  • Iruzibieta, Paula
  • Crespo, Javier
  • Lu, Shelly C.
  • Varela Rey, Marta
  • Mato, José M.
  • Delgado, Teresa C.
  • Martínez Chantar, María L.
[EN]Glycine N-methyltransferase (GNMT) is the most abundant methyltransferase in the liver and a master regulator of the transmethylation flux. GNMT downregulation leads to loss of liver function progressing to fibrosis, cirrhosis, and hepatocellular carcinoma. Moreover, GNMT deficiency aggravates cholestasis-induced fibrogenesis. To date, little is known about the mechanisms underlying downregulation of GNMT levels in hepatic fibrosis and cirrhosis. On this basis, microRNAs are epigenetic regulatory elements that play important roles in liver pathology. In this work, we aim to study the regulation of GNMT by microRNAs during liver fibrosis and cirrhosis. Luciferase assay on the 3ʹUTR-Gnmt was used to confirm in silico analysis showing that GNMT is potentially targeted by the microRNA miR-873-5p. Correlation between GNMT and miR-873-5p in human cholestasis and cirrhosis together with miR-873-5p inhibition in vivo in different mouse models of liver cholestasis and fibrosis [bile duct ligation and Mdr2 (Abcb4)-/- mouse] were then assessed. The analysis of liver tissue from cirrhotic and cholestatic patients, as well as from the animal models, showed that miR-873-5p inversely correlated with the expression of GNMT. Importantly, high circulating miR-873-5p was also detected in cholestastic and cirrhotic patients. Preclinical studies with anti-miR-873-5p treatment in bile duct ligation and Mdr2-/- mice recovered GNMT levels in association with ameliorated inflammation and fibrosis mainly by counteracting hepatocyte apoptosis and cholangiocyte proliferation. In conclusion, miR-873-5p emerges as a novel marker for liver fibrosis, cholestasis, and cirrhosis and therapeutic approaches based on anti-miR-873-5p may be effective treatments for liver fibrosis and cholestatic liver disease., SI, This work was supported by grants from NIH (US Department of Health and Human services)- R01AT001576 (S.C.L., J.M.M., and M.L.M.-C.), Ministerio de Economía, Industria y Competitividad: SAF2017-87301-R (M.L.M.-C.), Gobierno Vasco-Departamento de Salud 2013111114 (to M.L.M.-C.), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD (M.L.M.-C.), ELKARTEK 2016, Departamento de Industria del Gobierno Vasco (to M.L.M.-C.), Asociación Española contra el Cáncer (to T.C.D, P.F.-T. and M.L.M.-C.), Mitotherapeutix (to M.L.M.-C.), Daniel Alagille award from EASL (to T.C.D), Fundación Científica de la Asociación Española Contra el Cancer (AECC Scientific Foundation) Rare Tumor Calls 2017 (to M.L.M, J.M.B., and M.A), La Caixa Foundation Program (to M.L.M, J.M.B.), FIS: PI15/00892 (to M.F.F), FIS: PI15/01132 and FIS PI18/01075 (to J.M.B.), (to J.M.B.), FIS: PI14/00399 and PI17/00022 (to M.J.P.), Miguel Servet Program (CON14/00129 to J.M.B.), Ramon y Cajal Program (RYC-2015-17755 to M.J.P.), GRUPIN14-052 (to M.F.), PI14/00962 Instituto Carlos III (to J.B.), AECC Scientific Foundation (to J.B.), World Wide Cancer Research (to J.B.), Programma di Ricerca Regione-Università 2007-2009 and 2011-2012, Regione Emilia-Romagna (to E.V.), “Diputación Foral Gipuzkoa” (DFG15/010, DFG16/004 to J.M.B.), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD to J.M.B.), Department of Health of the Basque Country (2013111173 to J.M.B.; 2015111100 to M.J.P.). Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III. “Hepacare Project” from Fundación La Caixa, Spain (to M.A.A and C.B.), BiO-Eusko Fundazioa project BIO15/CA/011 (to M.A.A and C.B.). We thank this work produced with the support of a 2017 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation (to M.V.R.). We thank MINECO for the Severo Ochoa Excellence Accreditation (SEV-2016-0644).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids

  • Ruiz de Gauna, Mikel
  • Biancaniello, Francesca
  • González-Romero, Francisco
  • Rodrigues, Pedro M.
  • Lapitz, Ainhoa
  • Gómez-Santos, Beatriz
  • Olaizola, Paula
  • Di Matteo, Sabina
  • Aurrekoetxea, Igor
  • Labiano, Ibone
  • Nieva, Ane
  • Benito-Vicente, Asier
  • Perrugorria, María J.
  • Apodaka, Maider
  • Paiva, Nuno A.
  • Sáenz de Urturi, Diego
  • Buqué, Xabier
  • Delgado, Igotz
  • Martín, César
  • Azkargorta, Mikel
  • Elortza, Félix
  • Calvisi, Diego F.
  • Andersen, Jesper B.
  • Álvaro, Domenico
  • Cardinale, Vincenzo
  • Bujanda, Luis
  • Banales, Jesús M.
  • Aspichueta, Patricia
[Background and Aims] Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with a dismal prognosis. We investigated if lipid metabolism is disrupted in CCA and its role in tumor proliferation., [Approach and Results] The in vitro and in vivo tumorigenic capacity of five human CCA cell lines was analyzed. Proteome, lipid content, and metabolic fluxes were evaluated in CCA cells and compared with normal human cholangiocytes (NHC). The Akt1/NOTCH1 intracellular cytoplasmic domain (Nicd1)-driven CCA mouse model was also evaluated. The proteome of CCA cells was enriched in pathways involved in lipid and lipoprotein metabolism. The EGI1 CCA cell line presented the highest tumorigenic capacity. Metabolic studies in high (EGI1) versus low (HUCCT1) proliferative CCA cells in vitro showed that both EGI1 and HUCCT1 incorporated more fatty acids (FA) than NHC, leading to increased triglyceride storage, also observed in Akt1/Nicd1-driven CCA mouse model. The highly proliferative EGI1 CCA cells showed greater uptake of very-low-density and HDLs than NHC and HUCCT1 CCA cells and increased cholesteryl ester content. The FA oxidation (FAO) and related proteome enrichment were specifically up-regulated in EGI1, and consequently, pharmacological blockade of FAO induced more pronounced inhibition of their tumorigenic capacity compared with HUCCT1. The expression of acyl-CoA dehydrogenase ACADM, the first enzyme involved in FAO, was increased in human CCA tissues and correlated with the proliferation marker PCNA., [Conclusions] Highly proliferative human CCA cells rely on lipid and lipoprotein uptake to fuel FA catabolism, suggesting that inhibition of FAO and/or lipid uptake could represent a therapeutic strategy for this CCA subclass., This work was supported by “Ayudas para apoyar grupos de investigación del sistema Universitario Vasco” (IT971‐16 to PA), MCIU/AEI/FEDER, UE (2018‐095134‐B‐100 to PA and by the University of Basque Country COLAB20/01 to PA; Spanish Carlos III Health Institute (ISCIII) (FIS PI15/01132, PI18/01075, PI21/00922, and Miguel Servet Program CON14/00129 and CPII19/00008 to JMB; FIS PI14/00399, PI17/00022 and PI20/00186 to MJP; Sara Borrell [CD19/00254 to PMR]) cofinanced by “Fondo Europeo de Desarrollo Regional” (FEDER); CIBERehd (ISCIII) to JMB, MJP, PMR, PA and LB); “Diputación Foral Gipuzkoa” (DFG15/010, DFG16/004 to JMB and 2020‐CIEN‐000067‐01 to PMR), Department of Health of the Basque Country (2019111024 to MJP, 2017111010 to JMB, and 2020111077 to JMB and PA), “Euskadi RIS3” (2016222001, 2017222014, 2018222029, 2019222054, 2020333010 to JMB), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD to JMB) and Department of Industry of the Basque Country (Elkartek: KK‐2020/00008 to JMB); La Caixa Scientific Foundation (HR17‐00601 to JMB). “Fundación Científica de la Asociación Española Contra el Cáncer” (AECC Scientific Foundation, to JMB). AMMF‐The Cholangiocarcinoma Charity (EU/2019/AMMFt/001, to JMB and PMR). MRDG was funded by “Fundación Científica de la Asociación Española Contra el Cáncer” (AECC de Bizkaia), MJP was funded by the Spanish Ministry of Economy and Competitiveness (MINECO: “Ramón y Cajal” Program RYC‐2015‐17755), IL, AL and FG‐R by the Basque Government (PRE_2016_1_0152, PRE_2018_2_0195 and PRE 2020 2 02500, respectively), AN‐Z and BG‐S by the UPV/EHU, AB‐V by “Programa de especialización de Personal Investigador Doctor” at the UPV/EHU (2019‐2020) and MA by the MCIU/AEI/FEDER., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis

  • Fernández-Ramos, David
  • Simón, Jorge
  • Fernández, Agustín F.
  • Fraga, Mario F.
  • Delgado, Teresa C.
  • Martínez-Chantar, María Luz
Fernández-Ramos et al., Glycine N-methyltransferase (GNMT) is the most abundant methyltransferase in the liver and a master regulator of the transmethylation flux. GNMT downregulation leads to loss of liver function progressing to fibrosis, cirrhosis, and hepatocellular carcinoma. Moreover, GNMT deficiency aggravates cholestasis-induced fibrogenesis. To date, little is known about the mechanisms underlying downregulation of GNMT levels in hepatic fibrosis and cirrhosis. On this basis, microRNAs are epigenetic regulatory elements that play important roles in liver pathology. In this work, we aim to study the regulation of GNMT by microRNAs during liver fibrosis and cirrhosis. Luciferase assay on the 3'UTR-Gnmt was used to confirm in silico analysis showing that GNMT is potentially targeted by the microRNA miR-873-5p. Correlation between GNMT and miR-873-5p in human cholestasis and cirrhosis together with miR-873-5p inhibition in vivo in different mouse models of liver cholestasis and fibrosis [bile duct ligation and Mdr2 (Abcb4)-/- mouse] were then assessed. The analysis of liver tissue from cirrhotic and cholestatic patients, as well as from the animal models, showed that miR-873-5p inversely correlated with the expression of GNMT. Importantly, high circulating miR-873-5p was also detected in cholestastic and cirrhotic patients. Preclinical studies with anti-miR-873-5p treatment in bile duct ligation and Mdr2-/- mice recovered GNMT levels in association with ameliorated inflammation and fibrosis mainly by counteracting hepatocyte apoptosis and cholangiocyte proliferation. In conclusion, miR-873-5p emerges as a novel marker for liver fibrosis, cholestasis, and cirrhosis and therapeutic approaches based on anti-miR-873-5p may be effective treatments for liver fibrosis and cholestatic liver disease., This work was supported by grants from NIH (US Department of Health and Human services)- R01AT001576 (S.C.L., J.M.M., and M.L.M.-C.), Ministerio de Economía, Industria y Competitividad: SAF2017-87301-R (M.L.M.-C.), Gobierno Vasco-Departamento de Salud 2013111114 (to M.L.M.-C.), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD (M.L.M.-C.), ELKARTEK 2016, Departamento de Industria del Gobierno Vasco (to M.L.M.-C.), Asociación Española contra el Cáncer (to T.C.D, P.F.-T. and M.L.M.-C.), Mitotherapeutix (to M.L.M.-C.), Daniel Alagille award from EASL (to T.C.D), Fundación Científica de la Asociación Española Contra el Cancer (AECC Scientific Foundation) Rare Tumor Calls 2017 (to M.L.M, J.M.B., and M.A), La Caixa Foundation Program (to M.L.M, J.M.B.), FIS: PI15/00892 (to M.F.F), FIS: PI15/01132 and FIS PI18/01075 (to J.M.B.), (to J.M.B.), FIS: PI14/00399 and PI17/00022 (to M.J.P.), Miguel Servet Program (CON14/00129 to J.M.B.), Ramon y Cajal Program (RYC-2015-17755 to M.J.P.), GRUPIN14-052 (to M.F.), PI14/00962 Instituto Carlos III (to J.B.), AECC Scientific Foundation (to J.B.), World Wide Cancer Research (to J.B.), Programma di Ricerca Regione-Università 2007-2009 and 2011-2012, Regione Emilia-Romagna (to E.V.), “Diputación Foral Gipuzkoa” (DFG15/010, DFG16/004 to J.M.B.), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD to J.M.B.), Department of Health of the Basque Country (2013111173 to J.M.B.; 2015111100 to M.J.P.). Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III. “Hepacare Project” from Fundación La Caixa, Spain (to M.A.A and C.B.), BiO-Eusko Fundazioa project BIO15/CA/011 (to M.A.A and C.B.). We thank this work produced with the support of a 2017 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation (to M.V.R.). We thank MINECO for the Severo Ochoa Excellence Accreditation (SEV-2016-0644)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease

  • Caballero-Camino, F. J.
  • Rivilla, I.|||0000-0003-1984-7183
  • Herraez, Elisa
  • Briz, O.
  • Santos-Laso, A.|||0000-0001-9810-4913
  • Izquierdo-Sanchez, Laura
  • Lee-Law, P. Y.
  • Rodrigues, P. M.|||0000-0001-6193-7436
  • Munoz-Garrido, P.
  • Jin, S.
  • Peixoto, E.
  • Richard, S.
  • Gradilone, S. A.
  • Perugorria, M. J.
  • Esteller, M.|||0000-0003-4490-6093
  • Bujanda, Luis|||0000-0002-4353-9968
  • Marin, J. J. G.
  • Banales, Jesus|||0000-0002-5224-2373
  • Cossío, Fernando P.|||0000-0002-4526-2122
Background and Aims: Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive development of symptomatic biliary cysts. Current surgical and pharmacological approaches are ineffective, and liver transplantation represents the only curative option. Ursodeoxycholic acid (UDCA) and histone deacetylase 6 inhibitors (HDAC6is) have arisen as promising therapeutic strategies, but with partial benefits. Approach and Results: Here, we tested an approach based on the design, synthesis, and validation of a family of UDCA synthetic conjugates with selective HDAC6i capacity (UDCA-HDAC6i). Four UDCA-HDAC6i conjugates presented selective HDAC6i activity, UDCA-HDAC6i #1 being the most promising candidate. UDCA orientation within the UDCA-HDAC6i structure was determinant for HDAC6i activity and selectivity. Treatment of polycystic rats with UDCA-HDAC6i #1 reduced their hepatomegaly and cystogenesis, increased UDCA concentration, and inhibited HDAC6 activity in liver. In cystic cholangiocytes UDCA-HDAC6i #1 restored primary cilium length and exhibited potent antiproliferative activity. UDCA-HDAC6i #1 was actively transported into cells through BA and organic cation transporters. Conclusions: These UDCA-HDAC6i conjugates open a therapeutic avenue for PLDs.